Abstract: A memory system includes a non-volatile memory and a memory controller that encodes data with an error correction code and stores the encoded data in the non-volatile memory. The memory controller executes first processing which is at least a part of first decoding processing using read information read from the non-volatile memory, uses statistical information of a processing result of the first processing to estimate a first indicator indicating a ratio of hard errors among bit errors in the read information, determines parameters for second decoding processing having a higher latency than the first processing according to the first indicator, and executes the second decoding processing by using the determined parameters and the read information.

Abstract: Capsular dosage forms containing polyunsaturated fatty acid (PUFA) compositions are provided herein. In certain embodiments, unit dosage forms comprising a plurality of millicapsules containing a PUFA composition therein are provided as well as their methods of use and manufacture. In certain embodiments, capsular dosage forms are provided herein that include a unit dosage form comprising a plurality of millicapsules containing a polyunsaturated free fatty acid substantially in free acid form. In some embodiments, the PUFA composition is Epanova®.

Abstract: Capsular dosage forms containing polyunsaturated fatty acid (PUFA) compositions are provided herein. In certain embodiments, unit dosage forms comprising a plurality of millicapsules containing a PUFA composition therein are provided as well as their methods of use and manufacture. In certain embodiments, capsular dosage forms are provided herein that include a unit dosage form comprising a plurality of millicapsules containing a polyunsaturated free fatty acid substantially in free acid form. In some embodiments, the PUFA composition is Epanova®.

Abstract: A water-soluble composition comprising (A) coenzyme Q10 of 5-40% by weight, (B) monoester of polyglycerol with average polymerization degree of 10 and fatty acid with 18 carbon atoms of 5-30% by weight, (C) mono-, di-, tri- or penta-ester of polyglycerol with average polymerization degree of 3-6 and fatty acid with 18 carbon atoms of 1-18% by weight, and (D) water, wherein its average particle diameter is 110 nm or smaller. It is superior in acid resistance, salt-resistance and heat resistance, and further enables to maintain the good water-soluble state being blended to medicines, foods and beverages, cosmetics, feeds, additives usually employed therein.

Abstract: It is intended to provide a preventive agent for ascites containing coenzyme Q which can sufficiently exert an effect on preventing ascites even when administering in a small dose and within a short period of time, and the preventive agent for ascites which can be effectively administered to poultry using a simple method. Namely, preventive agent for ascites in poultry containing coenzyme Q and a surfactant, wherein the content of the surfactant is in a range of between 0.5 and 80 parts by weight with respect to a total amount of the preventive agent for ascites.

Abstract: This invention relates to a composition comprising ubiquinone having superior dispersion-stability in an aqueous solution and high bioavailability. The ubiquinone(s) is dispersed and emulsified in an aqueous solution of a water-soluble material in the presence of an organic acid(s) to form a protective colloid, the average particle size of the suspended particles being not more than 5 ?m. The liquid composition can be adsorbed in or carried on an excipient, or dried.

Abstract: A water-soluble composition comprising (A) coenzyme Q10 of 5-40% by weight, (B) monoester of polyglycerol with average polymerization degree of 10 and fatty acid with 18 carbon atoms of 5-30% by weight, (C) mono-, di-, tri- or penta-ester of polyglycerol with average polymerization degree of 3-6 and fatty acid with 18 carbon atoms of 1-18% by weight, and (D) water, wherein its average particle diameter is 110 nm or smaller. It is superior in acid resistance, salt-resistance and heat resistance, and further enables to maintain the good water-soluble state being blended to medicines, foods and beverages, cosmetics, feeds, additives usually employed therein.

Abstract: It is intended to provide a preventive agent for ascites containing coenzyme Q which can sufficiently exert an effect on preventing ascites even when administering in a small dose and within a short period of time, and the preventive agent for ascites which can be effectively administered to poultry using a simple method. Namely, preventive agent for ascites in poultry containing coenzyme Q and a surfactant wherein the content of the surfactant is in a range of between 0.5 and 80 parts by weight with respect to a total amount of the preventive agent for ascites.

Abstract: This invention relates to a composition comprising ubiquinone having superior dispersion-stability in an aqueous solution and high bioavailability.

Abstract: A stabilized pharmaceutical composition containing 4-(3-tert.-butylamino-2-hydroxy)propoxy-2-methylisocarbostyril or an acid addition salt thereof as the active ingredient is now provided, in which the active ingredient compound is stabilized by addition of at least one of stabilizing agents selected from magnesium silicate, magnesium oxide, hydrotalcite and sodium hydrogen carbonate.